Check out the first part, of three, of my conversation with Panna Sharma, CEO of Lantern Pharma Inc. (Nasdaq: LTRN), for Pharmaceutical Executive, where he explains which specific endpoints they'll be looking at in the Phase I trial to assess LP-284's potential efficacy and how the insights gained will be fed back into RADR®
Miranda Schmalfuhs’ Post
More Relevant Posts
-
You may have seen parts of his video interview... but be sure to check out my FULL conversation, including some bonus insights that didn't make the videos, with Jim Shehan of Lowenstein Sandler LLP below!
In this exclusive podcast, Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler LLP, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more. Listen to the full podcast: https://ow.ly/I63M50SzElE
